Citron Reports Further Results from Laboratory Testing:
Questcor is Deceiving the FDA and Investors
H.P. Acthar Gel’s Specified Active Ingredient Less Than 20% of the Label Specification
Bioactivity of Deamidated Hormone Fragment Far Lower than Pure ACTH
The FDA has been Notified
Citron reports on further lab data submitted to FDA, that the contents Questcor's only revenue-generating drug product, H.P. Acthar Gel, does not match its label or the official product insert the label. Questcor spins one story for Wall Street, and another for the medical community, but the regulatory risk here cannot be overstated.
(As always, Citron recommends that you download the .PDF file locally, and click to follow the links.)
Citron Research comments on the difference between a cult stock, a dream stock, and a casino stock.
Behind the moonshot chart, Citron examines a litany of Plug Power (NASDAQ:PLUG) management's broken promises, a doomed business model, and some true penny-stock capital raises just last year. With no fundamental changes now or expected in its business model, this one has "bust" written all over it.